3 of the Best Dividend Stocks to Buy in May 2026

The article highlights AbbVie, Verizon, and Canadian Natural Resources as attractive dividend stocks, with yields of 3.4%, 5.9%, and 3.8%, respectively, and all trading at relatively low forward P/E multiples. AbbVie’s revenue rose more than 12% in its latest quarter, Verizon cited growth potential from its Frontier acquisition, and Canadian Natural has raised its dividend for 26 consecutive years. The piece is broadly positive but mostly opinion-driven, so the likely market impact is limited.

Analysis

This is a quality-plus-income basket, but the market is treating each name as a different macro expression: ABBV is a self-help compounder, VZ is a duration proxy with bond-like cash flows, and CNQ is an oil beta vehicle with a dividend attached. The second-order effect is that these are not just yield plays — they are capital allocation signals: each management team is effectively saying free cash flow is durable enough to support payouts while still funding growth or balance-sheet repair, which tends to compress equity risk premiums when rates stabilize.

The cleanest upside asymmetry is in ABBV. The market still prices it with a “post-patent-cliff” discount, but that discount becomes too punitive if new-product mix continues offsetting Humira at the current pace; the key catalyst is not the next quarter’s headline growth, but whether investors re-rate terminal earnings power over the next 6–12 months. If execution remains steady, ABBV can screen like a low-teens multiple business with mid-single-digit growth and a rising dividend, which is rare in large-cap healthcare.

VZ is a different setup: the stock’s yield only matters if leverage stays controlled and fiber integration actually improves ARPU, churn, and cross-sell. The Frontier deal creates a multi-quarter integration window where execution can either justify a re-rating or trap the stock in a high-yield value regime; the main risk is that financing costs and capex intensity eat the equity story before synergies show up. CNQ is the most macro-sensitive name: it benefits immediately from firmer crude, but the better trade is not “higher oil forever” — it is that the company can sustain payouts through a range of oil outcomes, making it attractive in a world where energy volatility remains elevated rather than trending.

The consensus is underappreciating that these are defensive income names with embedded optionality, not just yield substitutes for bonds. In a lower-rate environment, VZ’s equity duration should improve most; in a higher-for-longer or geopolitically stressed regime, CNQ’s FCF convexity dominates; and ABBV offers the best idiosyncratic rerating potential if growth durability becomes widely accepted. The mistake would be owning them as one uniform dividend factor — the spread between them is where the alpha sits.

Key Decisions for Investors

• Long ABBV on weakness for a 6-12 month re-rating trade; target a move toward a low-teens forward multiple if new-product growth stays intact. Use a tight thesis stop if revenue growth decelerates materially for two consecutive quarters.
• Buy VZ only as a yield-plus-execution position, ideally after post-integration pullbacks over the next 2-3 quarters. Risk/reward improves if long-dated rates stabilize; downside is a value trap if fiber synergies fail to offset leverage and capex.
• Maintain/add CNQ as a tactical inflation/geopolitical hedge over the next 3-9 months. Best entry is on crude pullbacks; trim if oil rallies sharply enough that the equity rerates beyond its historical FCF multiple range.
• Pair trade: long ABBV / short VZ as a relative-quality expression over 6 months. ABBV has better earnings visibility and more credible compounding, while VZ remains more exposed to balance-sheet and integration risk.
• For income mandates, prefer a barbell of ABBV + CNQ rather than an equal-weight basket. That captures both idiosyncratic growth durability and commodity convexity without overexposing the portfolio to rate-sensitive telecom beta.